Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CD8A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 alpha chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD8A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF17 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 17 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD79B Biologics Sequence Review Report 2026: B-cell antigen receptor complex-associated protein beta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD79B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR2C Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-c Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR2B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-b Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD247 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 zeta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD247 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR50 Biologics Sequence Review Report 2026: Melatonin-related receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR50 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRD1 Biologics Sequence Review Report 2026: Natural killer cells antigen CD94 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRB1 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily B member 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRJ Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase eta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRJ protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRC3 Biologics Sequence Review Report 2026: NKG2-E type II integral membrane protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRC3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR143 Biologics Sequence Review Report 2026: G protein-coupled receptor 143 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR143 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.